|
NR 10-12/2007
|
|
|
|
|
|
|
|
|
Zastosowanie
ranibizumabu w leczeniu wysiękowego AMD – doświadczenia własne
Ranibizumab for treatment of
exudative age-related macular degeneration – own experience
Halina Wykrota, Ariadna Gierek-Łapińska,
Krzysztof Trzciąkowski, Urszula Gajdzik-Gajdecka
Samodzielny Publiczny Szpital Kliniczny Nr 5 Śląskiego
Uniwersytetu Medycznego w Katowicach
Dyrektor: prof. dr hab. n. med. Ariadna Gierek-Łapińska |
|
|
| Summary: |
It is commonly agreed
nowadays that one of the key elements of neovascular
age-related macular degeneration (AMD) pathogenesis is
deregulation of the angiogenesis factors. Treatment of
subfoveal choroidal neovascularizations (CNV) in course
of AMD was limited to photodynamic therapy with
verteporfin (PDT). The new approach to CNV treatment is
to discover and eliminate factors, which directly induce
CNV development. Extended studies have allowed to employ
inhibitors of vascular endothelial growth factor (VEGF)
for a treatment of neovascular AMD. Numerous of
anti-VEGF compounds are still under developing in
pre-clinical or phase-1/2 clinical studies whereas 2 of
them have completed phase 3 of clinical trials. The
newest compound that was launched on drug market is
ranibizumab (Lucentis®). Ranibizumab is a recombinant
humanized IgG1 isotype, monoclonal antibody fragment
designed for intravitreal use. Ranibizumab binds to and
inhibits the biologic activity of human vascular
endothelial growth factor A (VEGF-A). It has been proved
on the base of MARINA and ANCHOR clinical trials that
treatment ranibizumab is effective and save for patients
treated for CNV secondary to AMD.
Purpose: Interventional case series.
Material and methods: 67 eyes of 67 patients with
all angiographic subtypes of wet AMD were treated with
0.5 mg of intravitreal ranibizumab, injected monthly for
first 3 doses. Next doses were injected according to
specified re-treatment criteria as assessed in monthly
follow-up.
Results: Mean change in visual acuity (VA) was
+12.4 ETDRS letters. Percent of patient losing less than
15 ETDRS letters was 93.2%. Percent of patient gaining
VA more than 3 ETDRS letters was 43.4%.
Conclusions: Intravitreal ranibizumab is
effective in treatment of CNV due to AMD. A significant
number of patients have improved theirs VA.
Implementation of anti-VEGF therapy for treatment of
ocular diseases gave a new hope for patient that
previously couldn’t be treated with any of method. |
| Słowa kluczowe: |
zwyrodnienienie plamki
związane z wiekiem, neowaskularyzacje podsiatkówkowe,
czynnik wzrostu śródbłonka naczyń, ranibizumab. |
| Key words: |
age-related macular
degeneration, choroidal neovascularization, vascular
endothelial growth factor, ranibizumab. |
|
|
|
|
|
|
